CAREER OPPORTUNITY
Location: UBC Campus/UBC Hospital, Vancouver, BC
Category: Research Associate, Centre for Applied Neurogenetics, Laboratory of Translational Neuroscience
Department: Medical Genetics
Duration: 2012-12-01 to 2013-11-30
Type: Full-time; grant funded
Overview: The department of Medical Genetics at the University of British Columbia seeks applications for a Research Associate to investigate the neurobiology of disease.
POSITION SUMMARY
Dr. Matthew Farrer, Director of the Center for Applied Neurogenetics within the Department of Medical Genetics at the University of British Columbia, seeks applicants for a Research Associate position to investigate the pathophysiology and neurobiology of genetic determinants of neurodegenerative disease. The position is for one year with possibility of extension.
The successful applicant will joina dedicated, experienced and highly motivated team of neurogeneticists and neurobiologists. The work and environment is fast-paced and exciting, at the cutting edge of molecular insights into Parkinson’sand related diseases. Work is focused on the neurobiological characterization of novel genetic factors involved in neurodegeneration with the aim of translation to therapeutic development. Current foci are mutations in α-synuclein and leucine-rich repeat kinase 2, the two most prominent proteins implicated in Parkinson’s disease, in addition to mutations in two novel genes we have recently identified.
The successful candidate will formulate, design and lead research programs, generate proposals for external support from appropriate granting agencies, and be responsible for the training and supervision of postdoctoral fellows, graduate students and undergraduates in all aspects of their research. Proven leadership, mentoring, review and grant writing are essential.
Candidates are expected to think creatively in the design and execution of the research projects, and maximize the resources available for the successful neurobiological investigation of novel genetic causes of disease.
QUALIFICATIONS:
The successful candidate will hold a Ph.D. or equivalent degreein the field of neuroscience with experience in biochemistry and molecular biology. Applicants will have at least five years post-doctoral training and have demonstrated their research acumen with a strong track record of high profile international journal publication in the field of neurodegenerative disease. In addition the successful candidate must have:
- Broad knowledge of human molecular genetics, neurology and neuroscience
- Knowledge of cellular physiology, with emphasis on neuronal functions.
- Expertise in biochemistry, protein purification and protein interactions.
- Excellent scientific publication record and successful grant writing experience
- Proven project management, supervision and mentorship of laboratory staff. Experience providing hands-on assistance to trainees.
- Excellent communication skills including invited oral presentation at international conferences
- The ability to thrive in a high pressure, fast-paced and demanding team environment
- Drive and enthusiasm, to both lead and work as a member of a team
- Creativity, initiative and good judgment.
CONSEQUENCE OF ERROR/JUDGEMENT
The successful applicant will be directly responsible for errors in their work, for reporting problems and mistakes in a timely way, and for correcting those errors. Aspects of the research will be jointly reviewed by other Research Associates and Dr. Farrer.
HOW TO APPLY
If interested, please submit CV and three references to Susana Mendez Alcala at jobs@can.ubc.ca by midnight on October 31st, 2012.
UBC hires on the basis of merit and is committed to employment equity. All qualified persons are encouraged to apply. We especially welcome applications from members of visible minority groups, women, Aboriginal persons, persons with disabilities, persons of minority sexual orientations and gender identities, and others with the skills and knowledge to engage productively with diverse communities. Canadians and permanent residents of Canada will be given priority.